Subtractive Immunization as a Method to Develop Respiratory Syncytial Virus (RSV)—Specific Monoclonal Antibodies

Respiratory Syncytial Virus (RSV) is a significant cause of lower respiratory tract infections in the young, elderly, and immunodeficient patients. As such, virus represents an important morbidity mortality worldwide. Development monoclonal antibodies against RSV has resulted commercial prophylaxis, palivizumab (Synagis®), different that have improved our understanding structure viral proteins. In this study, immunization technique, subtractive immunization, was evaluated for its applicability to develop RSV-specific antibodies. One hybridoma which produced with strongest staining infected cells, ATAC-0025, selected further characterization. This antibody belongs IgG1 class, neutralizing capacity recognizes envelope F-protein. The broad reactivity range reference strains clinical isolates.